DelSiTech and Innovare Sign Licensing Agreement for the Development of a Long Acting HIV Therapy

Turku, Finland – 18 December 2018: DelSiTech Ltd, a Finnish drug delivery technology and drug development company and Innovare R&D, a leading Mexican pharmaceutical company, have signed a world-wide, exclusive licence agreement for the use of DelSiTech’s Silica Matrix drug delivery platform in the development and commercialisation of a long acting HIV therapy.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH